Carteolol
From Wikipedia, the free encyclopedia
|
Carteolol
|
|
| Systematic (IUPAC) name | |
| 5-[2-hydroxy-3- (tert-butylamino) propoxy]- 3,4-dihydro-1H-quinolin-2-one | |
| Identifiers | |
| CAS number | |
| ATC code | C07 S01ED05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C16H24N2O3 |
| Mol. mass | 292.373 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 85% |
| Metabolism | hepatic, active with 8-hyrdocarteolol |
| Half life | 6-8 hours |
| Excretion | Renal (50-70%) |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | oral |
Carteolol is a beta blocking agent
[edit] External links
- El-Kamel A, Al-Dosari H, Al-Jenoobi F. "Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.". Drug Deliv 13 (1): 55–9. doi:. PMID 16401594.
- Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). "Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro.". Cornea 24 (2): 213–20. doi:. PMID 15725891.
- Trinquand C, Romanet J, Nordmann J, Allaire C (2003). "[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]". J Fr Ophtalmol 26 (2): 131–6. PMID 12660585.
|
||||||||||||||||||||

